StockData
Inhibitor Therapeutics, Inc. logo

Inhibitor Therapeutics, Inc. (INTI) stock

INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)

Close on Oct 19, 2026Market cap $19.06MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$19.06M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$3.31M
EPS, diluted
-$0.01
Book value per share
-$0.01
Diluted shares
173M

Trading

Previous close
$0.11
Open
$0.11
Day's range
$0.11 – $0.11
Volume
0
Average volume (20 days)
6,526

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodINTIS&P 500DifferenceINTI per yearS&P 500 per year
1 month+23.6%+0.6%+23.0 pts
3 months+41.8%+3.4%+38.5 pts
Year to date+144.4%+13.3%+131.2 pts
1 year+129.2%+16.6%+112.6 pts
3 years+103.7%+86.4%+17.3 pts+26.8%+23.1%
5 years-31.3%+81.9%−113.1 pts-7.2%+12.7%
10 years-79.6%+318.9%−398.5 pts-14.7%+15.4%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$3.37M

Net income

-$3.31M

EPS, diluted

-$0.01
Reported periodTrailing twelve months

Press releases

Releases Inhibitor Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

About Inhibitor Therapeutics

Pharmaceutical Preparations

Inhibitor Therapeutics, Inc. is a pharmaceutical development company that focuses on repurposing approved active pharmaceutical ingredients to treat rare diseases, primarily targeting basal cell carcinoma nevus syndrome (Gorlin Syndrome). The company's lead development program centers on an oral formulation of itraconazole, an antifungal agent with anti-angiogenic properties that inhibit vascular growth supporting tumor proliferation. Its primary development candidate is a proprietary micronized and amorphous formulation developed to improve drug bioavailability and absorption for chronic disease management. The company currently operates without commercialized products, directing its activities toward preclinical and clinical evaluation to serve patients managed by dermatologists and Mohs micrographic surgeons.

Company profile, executives and history

Inhibitor Therapeutics stock: common questions

What is Inhibitor Therapeutics's stock price?

INTI closed at $0.11 on Oct 19, 2026, up 0.09% on the day.

What is Inhibitor Therapeutics's market cap?

Inhibitor Therapeutics was worth $19.06M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is INTI's P/E ratio?

Inhibitor Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.01), so it has no meaningful P/E ratio.

Does Inhibitor Therapeutics pay a dividend?

No. Inhibitor Therapeutics has not paid a cash dividend over the last twelve months.

How has INTI stock performed over the past year?

Including dividends, INTI returned +129.2% over the past year, against +16.6% for the S&P 500.

Who are Inhibitor Therapeutics's competitors?

Companies most similar to Inhibitor Therapeutics by business, industry and size include QNRX, VRCA, HIND, AZTR, PVLA.

See a number that looks wrong?